In March, Wegovy was approved by the Food and Drug Administration (FDA) to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease
10.1016/0968-000490148-x [DOI] [PubMed] [Google Scholar] 5.Mar M, de Gregorio E, de Dios C, Roca-Agujetas V, Cucarull B, Tutusaus A, et al
However, challenges such as poor bioavailability, complex multi-component formulations, and lack of standardization still hinder widespread use
Community protocols describe: Dosing together AM and/or PM CJC-1295 (no DAC): 100-300mcg per dose Ipamorelin: 200-300mcg per dose Administration on an empty stomach, 30+ min before food Learn more about CJC-1295 | Learn more about Ipamorelin Sermorelin + GHRP-2 A more aggressive pairing described by community sources seeking stronger GH output alongside appetite increase